Portrait of Patrick Bühler
PD Dr. Patrick Bühler

Making scientific discovery a patient and business reality.

I am Patrick Bühler, a scientist and inventor turned global business leader. I develop strategies that bring innovation to patients, combining marketing, market access and medical affairs into execution that delivers business results.

Associate Professor/Inventor/Global Business Strategist

Get in touch How I work
Leadership

Science creates possibility. Leadership makes it happen.

From designing breakthrough cancer immunotherapies to leading global market strategies, I have spent more than 20 years building innovative healthcare solutions from the ground up.

I am a coach at heart. Leading complex matrix teams and organisations across Roche's global network has taught me that sustainable success comes from identifying people's unique strengths and empowering them to exceed their own expectations.

My conviction is simple: great science must become commercially viable solutions that reach the patients who can benefit from them.

Always learning

  • Stanford Graduate School of Business: LEAD '26 alumnus
  • Harvard Business School: Generative AI Strategy and Execution, Boston (2026)
  • In progress: HBS Certificate of Specialization in Digital Transformation and AI
  • Academic: PhD in Molecular Oncology, Associate Professor of Medicine, MPhil in Publishing Studies
How I work

Where science, strategy and leadership meet.

I work with leadership teams, boards and audiences who want to turn innovation into impact.

Advisory

Strategic advice to leadership teams in pharma, biotech, diagnostics and medtech on portfolio, launch and commercial strategy.

Board consultancy

Support for boards on science-driven strategy, innovation, digital transformation and AI in healthcare.

Speaker

Keynotes and panels on healthcare innovation and leading at the interface of science and business.

Author

Inventor in cancer immunotherapy and author of 21 peer-reviewed publications in molecular oncology. View publications

Founder Stealth

Currently exploring a tech venture.

Publications

Research that laid the foundation.

Translational research on antibody-based diagnostics and immunotherapy of prostate cancer, including bispecific PSMA x CD3 diabodies that redirect T cells to destroy tumour cells.

21Original peer-reviewed articles
3Reviews and editorials
1,182Citations, Google Scholar
EP and USGranted patent family

Selected publications

Cancer Immunol Immunother 2008

A bispecific diabody directed against prostate-specific membrane antigen and CD3 induces T-cell mediated lysis of prostate cancer cells.

Bühler P, Wolf P, Gierschner D, Schaber I, Katzenwadel A, Schultze-Seemann W, Wetterauer U, Tacke M, Swamy M, Schamel WW, Elsässer-Beile U.

J Immunother 2009

Target-dependent T-cell activation by coligation with a PSMA x CD3 diabody induces lysis of prostate cancer cells.

Bühler P, Molnar E, Dopfer EP, Wolf P, Gierschner D, Wetterauer U, Schamel WWA, Elsässer-Beile U.

Prostate 2011

Effective targeting of prostate cancer by lymphocytes redirected by a PSMA x CD3 bispecific single-chain diabody.

Fortmüller K, Alt K, Gierschner D, Wolf P, Baum V, Freudenberg N, Wetterauer U, Elsässer-Beile U, Bühler P.

J Nucl Med 2009

PET imaging of prostate cancer xenografts with a highly specific antibody against the prostate-specific membrane antigen.

Elsässer-Beile U, Reischl G, Wiehr S, Bühler P, Wolf P, Alt K, Shively J, Judenhofer MS, Machulla H, Pichler BJ.

Full list

Original articles as first author 6
  1. Influence of structural variations on biological activity of anti-PSMA scFv and immunotoxins targeting prostate cancer.Bühler P, Wetterauer D, Gierschner D, Wetterauer U, Elsässer-Beile U, Wolf P.Anticancer Res 2010;30(9):3373-3379.
  2. Primary prostate cancer cultures are models for androgen-independent transit amplifying cells.Bühler P, Wolf P, Katzenwadel A, Schultze-Seemann W, Wetterauer U, Freudenberg N, Elsässer-Beile U.Oncol Rep 2010;23(2):465-470.
  3. Comparison of gene expression in LNCaP prostate cancer cells after treatment with bicalutamide or 5-alpha-reductase inhibitors.Bühler P, Fischer T, Wolf P, Gierschner D, Schultze-Seemann W, Wetterauer U, Elsässer-Beile U.Urol Int 2010;84(2):203-211.
  4. Target-dependent T-cell activation by coligation with a PSMA x CD3 diabody induces lysis of prostate cancer cells.Bühler P, Molnar E, Dopfer EP, Wolf P, Gierschner D, Wetterauer U, Schamel WWA, Elsässer-Beile U.J Immunother 2009;32(6):565-573.
  5. A bispecific diabody directed against prostate-specific membrane antigen and CD3 induces T-cell mediated lysis of prostate cancer cells.Bühler P, Wolf P, Gierschner D, Schaber I, Katzenwadel A, Schultze-Seemann W, Wetterauer U, Tacke M, Swamy M, Schamel WW, Elsässer-Beile U.Cancer Immunol Immunother 2008;57(1):43-52.
  6. Intravesical mistletoe extract for adjuvant treatment of superficial urinary bladder cancer.Bühler P, Leiber C, Lucht M, Wolf P, Wetterauer U, Elsässer-Beile U.Pharmacologyonline 2006;3:442-448.
Original articles as last author 2
  1. Effective targeting of prostate cancer by lymphocytes redirected by a PSMA x CD3 bispecific single-chain diabody.Fortmüller K, Alt K, Gierschner D, Wolf P, Baum V, Freudenberg N, Wetterauer U, Elsässer-Beile U, Bühler P.Prostate 2011;71(6):588-596.
  2. High-resolution animal PET imaging of prostate cancer xenografts with three different 64Cu-labeled antibodies against native cell-adherent PSMA.Alt K, Wiehr S, Ehrlichmann W, Reischl G, Wolf P, Pichler BJ, Elsässer-Beile U, Bühler P.Prostate 2010;70(13):1413-1421.
Original articles as co-author 13
  1. Pharmacokinetics and PET imaging properties of two recombinant anti-PSMA antibody fragments in comparison to their parental antibody.Wiehr S, Bühler P, Gierschner D, Wolf P, Rolle AM, Kesenheimer C, et al.Prostate 2014;74(7):743-755.
  2. Antitumor activities of PSMA x CD3 diabodies by redirected T-cell lysis of prostate cancer cells.Baum V, Bühler P, Gierschner D, Herchenbach D, Fiala GJ, et al.Immunotherapy 2013;5(1):27-38.
  3. Prostate-cancer-targeted N-(2-hydroxypropyl)methacrylamide copolymer/docetaxel conjugates.Liu J, Kopečková P, Pan H, Sima M, Bühler P, Wolf P, Elsässer-Beile U, et al.Macromol Biosci 2012;12(3):412-422.
  4. In vivo testing of 177Lu-labelled anti-PSMA antibody as a new radioimmunotherapeutic agent against prostate cancer.Behe M, Alt K, Deininger F, Bühler P, Elsässer-Beile U, Wolf P.In Vivo 2011;25(1):55-59.
  5. Three conformational antibodies specific for different PSMA epitopes are promising diagnostic and therapeutic tools for prostate cancer.Wolf P, Freudenberg N, Bühler P, Alt K, Schultze-Seemann W, et al.Prostate 2010;70(5):562-569.
  6. Preclinical evaluation of a recombinant anti-prostate specific membrane antigen single-chain immunotoxin against prostate cancer.Wolf P, Alt K, Wetterauer D, Bühler P, Gierschner D, Katzenwadel A, Wetterauer U, Elsässer-Beile U.J Immunother 2010;33(3):262-271.
  7. Biorecognition and subcellular trafficking of HPMA copolymer-anti-PMSA antibody conjugates by prostate cancer cells.Liu J, Kopečková P, Bühler P, Wolf P, Pan H, Bauer H, Elsässer-Beile U, Kopeček J.Mol Pharm 2009;6(3):959-970.
  8. PET imaging of prostate cancer xenografts with a highly specific antibody against the prostate-specific membrane antigen.Elsässer-Beile U, Reischl G, Wiehr S, Bühler P, Wolf P, Alt K, Shively J, Judenhofer MS, Machulla H, Pichler BJ.J Nucl Med 2009;50(4):606-611.
  9. Anti-PSMA immunotoxin as novel treatment for prostate cancer? High and specific antitumor activity on human prostate xenograft tumors in SCID mice.Wolf P, Alt K, Bühler P, Katzenwadel A, Wetterauer U, Tacke M, Elsässer-Beile U.Prostate 2008;68(2):129-138.
  10. A recombinant PSMA-specific single-chain immunotoxin has potent and selective toxicity against prostate cancer cells.Wolf P, Gierschner D, Bühler P, Wetterauer U, Elsässer-Beile U.Cancer Immunol Immunother 2006;55(11):1367-1373.
  11. A new generation of monoclonal and recombinant antibodies against cell-adherent prostate specific membrane antigen for diagnostic and therapeutic targeting of prostate cancer.Elsässer-Beile U, Wolf P, Gierschner D, Bühler P, Schultze-Seemann W, Wetterauer U.Prostate 2006;66(13):1359-1370.
  12. Immunological effects of an Echinacea purpurea extract in patients with breast cancer.Elsässer-Beile U, Rostock M, Bühler P, Wetterauer U, Schumacher M, Bartsch H.Pharmacologyonline 2006;3:474-481.
  13. Adjuvant intravesical treatment with a standardized mistletoe extract to prevent recurrence of superficial urinary bladder cancer.Elsässer-Beile U, Leiber C, Wetterauer U, Bühler P, Wolf P, Lucht M, Mengs U.Anticancer Res 2005;25(6C):4733-4736.
Reviews and editorials 3
  1. Bispecific antibodies and diabodies for cancer immunotherapy.Elsässer-Beile U, Bühler P.Immunotherapy 2012;4(5):459-460.
  2. Targeting the prostate-specific membrane antigen for prostate cancer therapy.Bühler P, Wolf P, Elsässer-Beile U.Immunotherapy 2009;1(3):471-481.
  3. Targeted therapies for prostate cancer against the prostate specific membrane antigen.Elsässer-Beile U, Bühler P, Wolf P.Curr Drug Targets 2009;10(2):118-125.
Patent 1
  1. Monoclonal antibodies and single chain antibody fragments against cell-surface prostate specific membrane antigen.Elsässer-Beile U, Wolf P, Gierschner D, Bühler P, Wetterauer U.EP 1 883 698 B1 (priority date 27.05.2005); US 8,198,416; US 8,632,777; US 9,238,694.
Third-party funding 2
  1. Preclinical development of a PSMA x CD3 diabody for the therapy of prostate cancer.Deutsche Krebshilfe. Bühler P (principal applicant), Elsässer-Beile U.
  2. PET and MR imaging of prostate cancer with specific anti-PSMA monoclonal antibodies and antibody fragments.Deutsche Forschungsgemeinschaft (DFG). Elsässer-Beile U, Bühler P, Pichler BJ.
Contact

Let us exchange perspectives.

On scientific innovation, business strategy and leading people towards meaningful outcomes.

Connect on LinkedIn

Companies

  • Roche
  • Ipsen
  • Ogilvy

Education

  • Stanford Graduate School of Business
  • University of Freiburg
  • University of Stirling

Executive Education

  • Harvard Business School
  • Harvard Law School

Logos shown for reference only. No endorsement implied.